Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06681688 · ClinicalTrials.gov registry record · Phase 1
Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC
A Phase 1 study of Cataract, sponsored by Inder Paul Singh, M.D..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 94
- Enrollment target
- 2
- Study locations
NCT06681688 is a Phase 1 study of Cataract that is actively recruiting participants, run by Inder Paul Singh, M.D.. The registered enrollment target is 94 participants, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (59% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06681688, a Phase 1 study of Cataract, is actively recruiting participants, sponsored by Inder Paul Singh, M.D..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 94 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multicenter, 2-arm, randomized, prospective study of patients slated for bilateral cataract extraction. One eye will be randomized to the Study Arm, and the fellow eye will be randomized to the Control Arm.
Conditions Studied
Interventions
- DRUG Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}
- DRUG Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}
Study Locations (2)
Florida
- The Eye Associates - Venice - Venice
Wisconsin
- The Eye Centers of Racine & Kenosha - Racine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2025-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06681688
The ClinicalTrials.gov registry entry for NCT06681688 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 227-participant average among 83 other Cataract trials with a reported enrollment target (59% lower). The listed sponsor is Inder Paul Singh, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide} is the first listed.
NCT06681688 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06681688 about?
NCT06681688 is a clinical study titled "Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC". This is a multicenter, 2-arm, randomized, prospective study of patients slated for bilateral cataract extraction. One eye will be randomized to the Study Arm, and the fellow eye will be randomized to the Control Arm.
What is the current status of trial NCT06681688?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 94 participants. The study started on 2024-07-10. Estimated completion is 2025-08.
What conditions does trial NCT06681688 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT06681688?
The interventions under investigation include: Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide} (DRUG), Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte} (DRUG).
Who is sponsoring clinical trial NCT06681688?
This trial is sponsored by Inder Paul Singh, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06681688 being conducted?
This trial has 2 study locations across Florida, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
RECRUITING
-
Effective Phaco Time and Endothelial Cell Loss When Using Veritas
RECRUITING
-
Evaluation of Head-Mounted Spatial Computing and Three-Dimensional (3D) Visualization in Ocular Microsurgery: A Safety and Workflow Study
RECRUITING · NA
-
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
RECRUITING · Phase 3
-
Unity VCS: A Comparison Study Evaluating Corneal Clarity and Thickness
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.